UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material under §240.14a-12

Iterum Therapeutics plc

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

No fee required.

 

 

Fee paid previously with preliminary materials.

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

img39799937_0.jpg 

 

Important notice regarding availability of proxy materials for the shareholder meeting to be held on january 30, 2024 your vote counts! Iterum therapeutics plc 2024 extraordinary general meeting january 30, 2024 3:00 pm, irish time (10:00 am et) iterum therapeutics plc fitzwilliam court, 1st floor leeson close dublin 2, ireland v27294-s77939 you invested in iterum therapeutics plc and it’s time to vote! You have the right to vote on proposals being presented at the extraordinary general meeting. Get informed before you vote view the proxy statement and notice of extraordinary general meeting online at www.proxyvote.com or you can receive a free paper or email copy of the material(s) by requesting prior to january 16, 2024. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.proxyvote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. To view the proxy materials and to vote, visit www.proxyvote.com control # smartphone users point your camera here and vote without entering a control number vote in advance of the meeting vote by january 30, 2024 4:59 a.m. Irish time (11:59 pm et, january 29) visit www.proxyvote.com vote in person at the meeting* january 30, 2024 3:00 pm irish time (10:00 am et) 3 dublin landings north wall quay dublin 1, ireland *please check the meeting materials for any special requirements for meeting attendance and for information on how to obtain directions to be able to attend the meeting. At the meeting, you will need to request a ballot to vote these shares. V1.1 1.

 


 

 

img39799937_1.jpg 

 

Vote at www.proxyvote.com this is not a votable ballot This is an overview of the more complete proxy materials, which contain important information, that are available to you on The internet. We encourage you to access and review all of the information contained in the proxy materials before voting. Please follow the instructions on the reverse side to vote these important matters. Voting items board Recommends 1. To grant the board of directors authority under irish law to allot and issue an additional 5,000,000 ordinary shares (including rights to acquire shares) for cash without first offering those shares to existing shareholders under pre-emptive rights that would otherwise apply to the issuance. For note: if any other matters properly come before the meeting or any adjournment thereof, the person(s) named in the proxy will vote in their discretion in accordance with applicable law or rule. For prefer to receive an email instead? While voting on www.proxyvote.com, be sure to click “delivery settings”. V27295-s77939

 



Iterum Therapeutics (NASDAQ:ITRM)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Iterum Therapeutics.
Iterum Therapeutics (NASDAQ:ITRM)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Iterum Therapeutics.